Olsen EA, Rosen ST, Vollmer RT, et al. Interferon alfa-2a in the treatment of cutaneous T cell lymphoma[J]. J Am Acad Dermatol, 1989, 20(3): 395-407.
[2]
Kaplan EH, Rosen ST, Norris DB, et al. Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma[J]. J Nati Cancer Inst, 1990, 82(3): 208-212.
[3]
Vonderheid EC, Thompson R, Smiles KA, et al. Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy[J]. Arch Dermatol, 1987, 123(6): 757-763.
[4]
Jumbou O, N’Guyen JM, Tessier MH, et al. Long-term follow-up in 51 patients with mycosis fungoides and Sezary syndrome treated by interferon-alfa[J]. Br J Dermatol, 1999, 140(3): 427-431.
[5]
Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)[J]. Blood, 2007, 110(6): 1713-1722.
[6]
Wolff JM, Zitelli JA, Rabin BS, et al. Intralesional interferon in the treatment of early mycosis fungoides[J]. J Am Acad Dermatol, 1985, 13(4): 604-612.
[7]
Vonderheid EC, Thompson R, Smiles KA, et al. Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy[J]. Arch Dermatol, 1987, 123(6): 757-763.
Dréno B, Claudy A, Meynadier J, et al. The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-alpha 2a and etretinate[J]. Br J Dermatol, 1991, 125(5): 456-459.
[10]
Hugh Z, Thestrup-Pedersen K. Interferon alpha and etretinate combination treatment of cutaneous T-cell lymphoma[J]. J Invest Dermatol, 1990, 95(Suppl 6): 206S-208S.
[11]
Shimauchi T, Sugita K, Nishio D, et al. Alterations of serum Th1 and Th2 chemokines by combination therapy of interferon-gamma and narrowband UVB in patients with mycosis fungoides[J]. J Dermatol Sci, 2008, 50(3): 217-225.
[12]
Bunn PA, Foon KA, Inde DC, et al. Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas[J]. Ann Intern Med, 1984, 101(4): 484-487.
[13]
Kohn EC, Steis RG, Sausville EA, et al. Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sezary syndrome[J]. J Clin Oncol, 1990, 8(1): 155-160.
[14]
Siegel RS, Pandolfino T, Guitart J, et al. Primary cutaneous T-cell lymphoma: review and current concepts[J] . J Clin Oncol, 2000, 18(15): 2908-2925.
[15]
Apisarnthanarax N, Duvic M. Cutaneous T-cell lymphoma. New immunodulators[J]. Dermatol Clin, 2001, 19(4): 737-740.
[16]
Jumbou O, N’Guyen JM, Tessier MH, et al. Long-term follow-up in 51 patients with mycosis fungoides and Sezary syndrome treated by interferon-alfa[J]. Br J Dermatol, 1999, 140(3): 427-431.
[17]
Bunn PA Jr, Hoffman SJ, Norris D, et al. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome)[J]. Ann Intern Med, 1994, 121(8): 592-602.
[18]
Chiarion-Sileni V, Bononi A, Fornasa CV, et al. Phase Ⅱ trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma[J]. Cancer, 2002, 95(3): 569-575.
[19]
Trautinger F, Knobler R, Willemze R, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome[J]. Eur J Cancer, 2006, 42(8): 1014-1030.
[20]
Zinzani PL, Mazza P, Gherlinzoni F. Beta interferon in the treatment of mycosis fungoides[J]. Haematologica, 1988, 73(6): 547-548.
